3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
3
Neoplasms
3
Venous Thrombosis
2
Thrombosis
2
Pancreatic Neoplasms
2
Thromboembolism
1
Stomach Neoplasms
1
Pulmonary Embolism
1
Ovarian Neoplasms
1
Obesity
1
Multiple Myeloma
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Embolism and Thrombosis
1
Embolism
1
Duodenal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Bevacizumab
69
Sorafenib
66
lenvatinib
59
durvalumab
38
sintilimab
33
Nivolumab
32
tislelizumab
28
atezolizumab
28
pembrolizumab
27
Oxaliplatin
26
tremelimumab
23
apatinib
22
Fluorouracil
22
Radiosurgery
20
regorafenib
19
camrelizumab
18
Doxorubicin
18
cabozantinib
16
Leucovorin
16
Capecitabine
16
Radiotherapy
14
Folfox protocol
14
donafenib
13
Gemcitabine
13
Cisplatin
12
toripalimab
11
Erlotinib Hydrochloride
10
spartalizumab
8
anlotinib
8
Neoadjuvant Therapy
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Hepatocellular
×
Dalteparin
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled